T1	Participants 87 137	retarding progression of coronary atherosclerosis.
T2	Participants 710 728	animals and humans
T3	Participants 1065 1137	data from the angiographic lipid-lowering trial REGRESS (pravastatin vs.
T4	Participants 1138 1146	placebo)
